HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy and safety of ticagrelor and clopidogrel in East Asian patients with coronary artery disease undergoing percutaneous coronary intervention.

AbstractAIMS:
The efficacy and safety of ticagrelor and clopidogrel in East Asian patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) remains uncertain. The purpose of this study was to compare the efficacy and safety of ticagrelor and clopidogrel in East Asian patients with CAD treated with PCI.
METHODS:
A total of 12383 patients with CAD undergoing PCI who received dual antiplatelet therapy (DAPT) were consecutively enrolled in the ticagrelor group (n = 1321) and the clopidogrel group (n = 11062). Major adverse cardiovascular and cerebrovascular events (MACCEs) and thrombolysis in myocardial infarction (TIMI) bleeding events were compared according to ticagrelor or clopidogrel use were compared.
RESULTS:
After propensity matching (n = 1321 in each group), ticagrelor was associated with lower incidence of MACCEs compared with clopidogrel (3.9 vs. 5.9%, hazard ratio [HR] = 0.65, 95% confidence interval [CI] 0.45-0.92, p = .015). The incidence of TIMI bleeding events was higher in the ticagrelor group than in the clopidogrel group (4.5 vs. 2.9%, HR = 1.90, 95% CI 1.25-2.88, p = .024). The difference between ticagrelor and clopidogrel for net adverse clinical events was nonsignificant (4.3 vs. 4.9%, HR = 0.88, 95% CI 0.61-1.27, p = .458).
CONCLUSIONS:
Ticagrelor was associated with a lower incidence of MACCEs and an increased risk of TIMI bleeding events in East Asian patients with CAD receiving PCI.
AuthorsJianan Li, Hong Qiu, Lirong Yan, Tingting Guo, Yong Wang, Yang Li, Jianfeng Zheng, Yida Tang, Bo Xu, Shubin Qiao, Yuejin Yang, Runlin Gao
JournalCurrent medical research and opinion (Curr Med Res Opin) Vol. 36 Issue 11 Pg. 1739-1745 (11 2020) ISSN: 1473-4877 [Electronic] England
PMID32945695 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Ticagrelor
Topics
  • Aged
  • Asian People
  • Clopidogrel (adverse effects, therapeutic use)
  • Coronary Artery Disease (drug therapy, mortality, surgery)
  • Female
  • Hemorrhage (etiology, prevention & control)
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction (etiology)
  • Percutaneous Coronary Intervention (adverse effects, methods)
  • Platelet Aggregation Inhibitors (administration & dosage, adverse effects, therapeutic use)
  • Preoperative Care
  • Ticagrelor (administration & dosage, adverse effects, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: